Mineralys [MLYS] vs Bio-Techne [TECH] Detailed Stock Comparison

Mineralys Therapeutics Inc.

NASDAQ
Loading...

Bio-Techne Corporation

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Mineralys Therapeutics Inc. wins in 3 metrics, Bio-Techne Corporation wins in 10 metrics, with 1 ties. Bio-Techne Corporation appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Mineralys Therapeutics Inc. Bio-Techne Corporation Better
P/E Ratio (TTM) N/A 117.16 N/A
Price-to-Book Ratio 3.63 4.55 Mineralys Therapeutics Inc.
Debt-to-Equity Ratio 0.00 20.07 Tie
PEG Ratio -15.73 -0.82 Bio-Techne Corporation
EV/EBITDA -10.06 28.87 Bio-Techne Corporation
Profit Margin (TTM) 0.00% 6.41% Bio-Techne Corporation
Operating Margin (TTM) 0.00% 14.51% Bio-Techne Corporation
EBITDA Margin (TTM) N/A 14.51% N/A
Return on Equity -36.91% 3.80% Bio-Techne Corporation
Return on Assets (TTM) -24.58% 6.09% Bio-Techne Corporation
Free Cash Flow (TTM) $-142.43M $256.55M Bio-Techne Corporation
Dividend Yield N/A 0.62% N/A
1-Year Return 102.18% 6.78% Mineralys Therapeutics Inc.
Price-to-Sales Ratio (TTM) N/A 7.35 N/A
Enterprise Value $1.71B $9.19B Bio-Techne Corporation
EV/Revenue Ratio N/A 7.56 N/A
Gross Profit Margin (TTM) N/A 62.72% N/A
Revenue per Share (TTM) N/A $8 N/A
Earnings per Share (Diluted) $-2.29 $0.49 Bio-Techne Corporation
Beta (Stock Volatility) 0.69 1.47 Mineralys Therapeutics Inc.
Short % of Float 12.33% 5.09% Bio-Techne Corporation

Mineralys Therapeutics Inc. vs Bio-Techne Corporation Stock Performance Analysis

Loading Price Chart...

MLYS
TECH

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Mineralys Therapeutics Inc.-13.14%-16.49%-15.48%-12.10%-36.07%-29.82%
Bio-Techne Corporation2.17%5.74%-7.11%-10.77%-20.32%-14.75%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Mineralys Therapeutics Inc.102.18%113.99%70.82%70.82%70.82%70.82%
Bio-Techne Corporation6.78%-37.73%-51.28%86.91%161.27%281.12%

Performance & Financial Health Analysis: Mineralys Therapeutics Inc. vs Bio-Techne Corporation

MetricMLYSTECH
Market Information
Market Cap i$2.37B$9.07B
Market Cap CategoryMid capMid cap
10 Day Avg. Volume i1,136,5102,151,790
90 Day Avg. Volume i1,430,5402,370,067
Last Close$25.06$50.85
52 Week Range$12.59 - $47.65$43.20 - $72.16
% from 52W High-47.41%-29.53%
All-Time High$47.60 (Nov 12, 2025)$135.96 (Sep 20, 2021)
% from All-Time High-47.35%-62.60%
Growth Metrics
Quarterly Revenue GrowthN/A-0.01%
Quarterly Earnings GrowthN/A0.14%
Financial Health
Profit Margin (TTM) i0.00%0.06%
Operating Margin (TTM) i0.00%0.15%
Return on Equity (TTM) i-0.37%0.04%
Debt to Equity (MRQ) i0.0020.07
Cash & Liquidity
Book Value per Share (MRQ)$7.93$12.62
Cash per Share (MRQ)$7.97$0.93
Operating Cash Flow (TTM) i$-142,416,000$251.25M
Levered Free Cash Flow (TTM) i$-84,379,504$274.30M
Dividends
Last 12-Month Dividend Yield iN/A0.62%
Last 12-Month Dividend iN/A$0.40

Valuation & Enterprise Metrics Analysis: Mineralys Therapeutics Inc. vs Bio-Techne Corporation

MetricMLYS (Apr 22, 2026)TECH (Nov 10, 2025)
Price Ratios
P/E Ratio (TTM) iN/A117.16
Forward P/E i-15.7326.21
PEG Ratio i-15.73-0.82
Price to Sales (TTM) iN/A7.35
Price to Book (MRQ) i3.634.55
Market Capitalization
Market Capitalization i$2.37B$9.07B
Enterprise Value i$1.71B$9.19B
Enterprise Value Metrics
Enterprise to Revenue iN/A7.56
Enterprise to EBITDA i-10.0628.87
Risk & Other Metrics
Beta i0.691.47
Book Value per Share (MRQ) i$7.93$12.62

Financial Statements Comparison: Mineralys Therapeutics Inc. vs Bio-Techne Corporation

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricMLYS (2025)TECH (2025)
Revenue/Sales i01.22B
Cost of Goods Sold iN/A429.36M
COGS % of Revenue i-35.2%
Gross Profit iN/A790.27M
Gross Margin i-64.8%
Research & Development i132.01M99.50M
Operating Income (EBIT) i-170.60M242.80M
Operating Margin i-19.9%
EBITDA i-170.55M357.57M
EBITDA Margin i-29.3%
Pre-Tax Income i-154.65M98.46M
Pre-Tax Income % of Revenue i-8.1%
Income Tax iN/A25.06M
Income Tax % of Revenue i-2.1%
Net Income (Profit) i-154.65M73.40M
Profit Margin i-6.0%

Balance Sheet & Liquidity Metrics

MetricMLYS (2025)TECH (2025)
Cash & Equivalents i172.92M162.19M
Total Current Assets i661.39M608.30M
Total Current Assets % of Revenue i-49.9%
Total Current Liabilities i15.11M175.85M
Total Current Liabilities % of Revenue i-14.4%
Long-Term Debt iN/A429.96M
Long-Term Debt % of Revenue i-35.3%
Total Shareholders Equity i646.69M1.92B
Retained Earnings i-457.17M1.07B
Retained Earnings % of Revenue i-87.4%
Property, Plant & Equipment iN/A73.40M

Cash Flow Statement Comparison

MetricMLYS (2025)TECH (2025)
Operating Cash Flow i-145.31M185.64M
Operating Cash Flow % of Revenue i-15.2%
Capital Expenditures i-15,000-31.01M
Free Cash Flow i-142.43M256.55M
FCF Margin i-21.0%
Debt Repayment iN/A-77.00M
Common Stock Repurchase iN/A-275.73M

Short Interest & Institutional Ownership Analysis

MetricMLYSTECH
Shares Short i8.37M6.94M
Short Ratio i5.862.59
Short % of Float i12.33%5.09%
Shares Outstanding i81.54M154.97M
Float Shares i60.26M153.94M
% Held by Insiders i0.72%0.28%
% Held by Institutions i113.71%102.89%
% Held by Public i-14.43%-3.17%

Dividend Analysis & Yield Comparison: Mineralys Therapeutics Inc. vs Bio-Techne Corporation

MetricMLYSTECH
Last 12-Month Dividend iN/A$0.40
Last 12-Month Dividend Yield iN/A0.62%
3-Year Avg Annual Dividend iN/A$0.32
3-Year Avg Dividend Yield iN/A0.12%
3-Year Total Dividends iN/A$0.96
Ex-Dividend DateN/AFeb 13, 2026